Shingles at 79: Does a Longer Antiviral Course Actually Prevent the Nerve Pain After
A single patient, 79 years old, with severe acute shingles pain and every risk factor for the nerve pain that can outlast the rash by months. The disagreement is whether stretching the antiviral course beyond the standard week actually lowers that risk, or just extends a drug that's already done its job.
E.F., a 79-year-old retired church organist, developed a painful, blistering rash across her left chest wall three days ago — the kind of burning, stabbing pain she describes as worse than either of her two prior kidney stones, severe enough that she's barely slept and has stopped playing the piano she still practices most afternoons. She has no history of zoster before now, never received the zoster vaccine (her PCP raised it twice, she kept meaning to schedule it), and is otherwise healthy apart from well-controlled hypertension. Her age alone puts her in the highest-risk group for postherpetic neuralgia, and the severity of her acute pain compounds that risk further — both are established, independent predictors that a meaningful fraction of zoster patients her age go on to have pain persisting well past their rash healing, sometimes for months.
Standard antiviral therapy for acute zoster runs seven days, a duration set by trials measuring rash healing and acute pain resolution, not by a trial specifically designed to test whether extending therapy changes PHN incidence. Beutner's own randomized comparison of seven versus fourteen days of valacyclovir found no added benefit from the longer course on zoster-associated pain. The honest evidence gap the team is working around: the drugs clearly reduce acute pain severity and duration, and acute pain severity is itself one of the strongest known predictors of who goes on to develop PHN, which creates a plausible indirect argument for more aggressive early treatment — but "more aggressive early treatment lowers PHN risk" and "a longer course specifically, beyond seven days, lowers PHN risk further" are not the same claim, and Beutner's seven-versus-fourteen-day valacyclovir comparison, along with dedicated trials extending antiviral duration past the standard course, hasn't shown an independent PHN benefit from duration alone. She is in the room today, on day three, with vesicles still forming and nothing yet crusted — which is to say the standard course is already positioned to do everything it has ever been shown to do, and the only thing still unwritten is what goes on the line beneath it.
Urgent care, day three of rash
I'd give her the standard seven-day valacyclovir course and put real effort into pain control alongside it, not a longer antiviral run. Trials that specifically tested extending antiviral duration past the standard course haven't shown an independent PHN benefit from the extra days — the evidence just doesn't support that a longer course is doing more protective work than the standard one.
If a dedicated duration trial existed showing real PHN benefit from extending therapy, I'd change my position immediately — this is about what's actually been tested, not a fixed preference for shorter courses.
I'd extend the course anyway, given how stacked her risk profile is — age 79 plus severe acute pain, both independent PHN predictors in the same patient. I know the dedicated duration trial doesn't exist, but the biological logic (more sustained suppression during active nerve involvement) is reasonable, the drug is well-tolerated, and the downside of a few extra days is small next to months of neuralgia if we're wrong to stop at seven.
I'm not disputing what the trials actually showed — I'm saying absence of a dedicated positive trial isn't the same as evidence against benefit, and for a low-toxicity drug in a high-risk patient, I'd rather act on a plausible mechanism than wait for a trial that may never get funded.
I'd keep the antiviral at standard duration and redirect the actual precaution toward analgesia. Acute pain severity is one of the best-established predictors of PHN we have — her 8-out-of-10 pain on acetaminophen alone is itself the modifiable variable that's been shown to matter, and it's currently undertreated. That's where I'd spend the "precautionary" instinct, not on stretching a drug course past where its own benefit was actually measured.
Gabapentin started now, titrated over the next several days, treats the risk factor we actually have evidence for. A longer antiviral course treats a hypothesis we don't.
Agreed: standard 7-day valacyclovir course, gabapentin started and titrated over the following days, and a follow-up call scheduled at day seven to reassess both her rash and her pain control specifically.
Not fully resolved: the primary care physician's precautionary instinct toward extending the antiviral course wasn't judged wrong to hold, only not adopted as today's plan given the actual trial evidence. The team agreed to revisit antiviral duration specifically if her pain remains severe and poorly controlled at the seven-day mark, rather than treating today's decision as closed regardless of how she responds.